ABBV Earnings Prediction
The chart below shows how ABBV performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ABBV sees a -1.62% change in stock price 10 days leading up to the earnings, and a +0.28% change 10 days following the report. On the earnings day itself, the stock moves by +0.66%. This data can give you a slight idea of what to expect for the next quarter's release.
ABBV Key Earning Data
ABBV Earnings Analysis
Positive
Earnings Per Share Surge: Full year adjusted earnings per share reached $10.12, exceeding initial guidance by $0.49, demonstrating strong financial performance.
Revenue Surpasses Guidance: Total net revenues for the year were $5.63 billion, surpassing initial guidance by over $2 billion, reflecting a 4.6% operational growth despite significant HUMIRA erosion.
Sales Growth Acceleration: The ex HUMIRA platform achieved over 18% sales growth for the year, accelerating to 22% in the fourth quarter, indicating robust market performance.
Projected Revenue Surge: SKYRIZI and RINVOC are projected to generate nearly $24 billion in revenue for 2025, reflecting an increase of over $6 billion from previous estimates, driven by strong market capture.
Neuroscience Sales Growth: The neuroscience segment is expected to deliver $10 billion in sales for 2025, reflecting a $1 billion increase year-over-year, showcasing strong growth across key therapeutic areas.
Negative
HUMIRA Sales Decline: Total HUMIRA sales declined by 48.7% on an operational basis, primarily due to increased biosimilar competition, resulting in a significant revenue loss.
Aesthetics Sales Decline: Aesthetics segment reported a global sales decline of approximately 4.4%, with U.S. sales down 5%, attributed to challenging market conditions and suppressed consumer spending.
Imbruvica Revenue Decline: IMBRUVICA global revenues decreased by 6.2%, reflecting continued competitive dynamics in chronic lymphocytic leukemia (CLL), indicating pressure on this key oncology product.
Aesthetics Market Decline: The aesthetics market in China faced economic headwinds, contributing to a 3.2% operational decline in international aesthetics sales, highlighting vulnerability in key markets.
Operating Margin Impact: The adjusted operating margin ratio was impacted by a 10.4% unfavorable effect from acquired IP R&D expenses, indicating increased costs affecting profitability.
ABBV FAQs
How does ABBV typically perform around its earnings report dates?
ABBV's stock performance around earnings reports can vary, but historical data shows specific patterns, such as a -1.62% change leading up to the report and a +0.28% change in the 10 days following the release.
